

Figure S1. EIF4G1 protein level in human cancers and normal tissues. (a) Protein levels of EIF4G1 in normal organs; (b) Protein levels of EIF4G1 in tumor tissues; (c) Representative IHC images of EIF4G1 expression level in BRCA tissues and normal samples.




Figure S2. The KM survival curves of the three subtypes of BRCA. (a) Hormone receptor (HR) positive/HER2 negative, (b) HER2 positive, (c) triple-negative in the TCGA cohort. (d) HR positive/HER2 negative, (e) HER2 positive, (f) triple-negative in the GSE88770 cohort.




Figure S3. KM survival stratification analyses of clinical characteristics pertaining to (a) early stage, (b) advanced stage, (c) age ≤ 58 , (d) age > 58 , (e) early grade, and (f) advanced grade.




Figure S4. The time-dependent ROC curve for 3-, 5-, and 7-year survival rates. (a) AUC predictive value of EIF4G1 in TCGA; (b) AUC predictive value of EIF4G1 for age >58, (c) early stage, (d) and advanced stage in TCGA; (e) AUC predictive value of EIF4G1 in meta-validation; (f) AUC predictive value of EIF4G1 for advanced grade in GEO.